Cambridgeand mid banner advertisement
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Mogrify mid banner
ARM Innovation Hub
Advertisement: Birketts mid banner
Advertisement: EBCam mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement mid banner S-Tech 1
Advertisement: Kao Data Centre mid banner
Advertisement: Cambridge Network mid banner
Advertisement: SATAVIA mid banner
Advertisement: partnersand mid banner
Mid banner advertisement: BDO
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
13 September, 2021 - 13:27 By Tony Quested

Philadelphia freedom as Boyds lands in the US

Boyds, the Cambridge pharmaceutical and biotech product development consultancy, has opened a US office in the Philadelphia area to support continued growth opportunities. 

The company has also appointed Katy Rudnick as VP and head of US Regulatory Affairs to head up the US business. 

Since Boyds was established in 2005 it has worked with US companies seeking to develop and gain approval for medicines in Europe and further afield. 

Boyds’ global reputation for its work in advanced therapies has led to a steady increase in the number of companies approaching it for services and  more than 60 per cent of the company’s client base is now anchored in the US.

The new office in Pennsylvania is regarded as an ideal location for many of Boyds’ East Coast clients and provides a link between different time zones from Europe to the West Coast.

Katy Rudnick brings 20 years of regulatory and quality experience in the US, having worked across all therapeutic areas and dosage forms. 

Prior to joining Boyds, Katy was Director of Regulatory Affairs at Lupin Pharmaceuticals where she was responsible for a product portfolio of around 400 products at various stages. She has also held regulatory roles at Lannett Company, Teva Pharmaceuticals and Mars Fishcare North America.

President and founder of Boyds, Professor Alan Boyd, said: “The US is the largest biotech market globally and we have a strong and growing client base in the US. 

“Opening the office in Pennsylvania is the natural next step for Boyds and having a presence on the ground will ensure we can work closely with US clients looking to develop and take their products forward for approval with regulators in the US, as well as the UK and Europe, via our UK and Dublin offices.”

Newsletter Subscription

Stay informed of the latest news and features